ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Cancer
Ovarian Cancer
Endometrial Cancer
Uterine Cervical Cancer

Triple Negative Breast Cancer trials near Cincinnati, OH, USA:

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Cincinnati, Ohio, United States and 14 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Cincinnati, Ohio, United States and 288 other locations

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 140 other locations

III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 258 other locations

to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...

Enrolling
Triple-Negative Breast Cancer
Biological: Pembrolizumab
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Edgewood, Kentucky, United States and 280 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 312 other locations

including metastatic colorectal cancer (mCRC) patients....

Enrolling
Cancer
Drug: cetuximab
Drug: FOLFIRI

Phase 1

Tizona Therapeutics

Cincinnati, Ohio, United States and 40 other locations

pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic c...

Enrolling
Small Cell Lung Cancer
Triple-negative Breast Cancer
Drug: JANX008

Phase 1

Janux Therapeutics

Cincinnati, Ohio, United States and 17 other locations

Researchers are looking for new ways to treat types of breast cancer that are both:* High-risk, which means the cancer may ...

Enrolling
Triple Negative Breast Neoplasms
Breast Neoplasms
Drug: Carboplatin
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Cincinnati, Ohio, United States and 233 other locations

farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer -...

Enrolling
Solid Tumor
Drug: Lenvatinib
Drug: Farletuzumab ecteribulin

Phase 1, Phase 2

Eisai
Eisai

Cincinnati, Ohio, United States and 58 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems